From Wikipedia, the free encyclopedia
  (Redirected from Detrol)
Jump to navigation Jump to search
Clinical data
Trade namesDetrol, Detrusitol, others
License data
  • AU: B3
Routes of
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingApproximately 96.3%
Elimination half-life1.9–3.7 hours
  • (S)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-methylphenol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.232.068 Edit this at Wikidata
Chemical and physical data
Molar mass325.496 g·mol−1
3D model (JSmol)
  • Cc1ccc(c(c1)[C@H](CCN(C(C)C)C(C)C)c2ccccc2)O
  • InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1 checkY

Tolterodine, sold under the brand names Detrol among others, is medication used to treat frequent urination, urinary incontinence, or urinary urgency.[1] Effects are seen within an hour.[2] It is taken by mouth.[2][3]

Common side effects include headache, dry mouth, constipation, and dizziness.[2] Serious side effects may include angioedema, urinary retention, and QT prolongation.[2] Use in pregnancy and breastfeeding are of unclear safety.[1][4] It works by blocking muscarinic receptors in the bladder thus decreasing bladder contractions.[2]

Tolterodine was approved for medical use in 1998.[2] It is available as a generic medication.[1] In 2017, it was the 229th most commonly prescribed medication in the United States, with more than two million prescriptions.[5][6]

Medical uses[edit]

Detrusor overactivity (DO, contraction of the muscular bladder wall) is the most common form of urinary incontinence (UI) in older adults. It is characterized by uninhibited bladder contractions causing an uncontrollable urge to void. Urinary frequency, urge incontinence and nocturnal incontinence occur. Abnormal bladder contractions that coincide with the urge to void can be measured by urodynamic studies. Treatment is bladder retraining,[7] pelvic floor therapy or with drugs that inhibit bladder contractions such as oxybutynin and tolterodine.

Side effects[edit]

Known side effects:

The following reactions have been reported in patients who have taken tolterodine since it has become available:

Tolterodine is not recommended for use in people with myasthenia gravis and angle closure glaucoma.


Tolterodine acts on M2 and M3[8] subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors.

Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.[citation needed]

Brand names[edit]

It is marketed by Pfizer in Canada and the United States by its brand name Detrol. In Egypt it is also found under the trade names Tolterodine by Sabaa and Incont L.A. by Adwia.


  1. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 762. ISBN 9780857113382.
  2. ^ a b c d e f "Tolterodine Tartrate Monograph for Professionals". American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  3. ^ Narain S, Parmar M (January 2021). "Tolterodine". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 32491781.
  4. ^ "tolterodine Use During Pregnancy". Retrieved 3 March 2019.
  5. ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  6. ^ "Tolterodine Tartrate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
  7. ^ "Bladder retraining". Interstitial Cystitis Association. Retrieved 6 June 2018.
  8. ^ "Tolterodine". DrugBank.

External links[edit]

  • "Tolterodine". Drug Information Portal. U.S. National Library of Medicine.